A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Fasinumab (Primary)
  • Indications Back pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 14 Sep 2017 Status changed from planning to not yet recruiting.
    • 14 Feb 2017 New trial record
    • 09 Feb 2017 This trial is expected to begin in 2017, according to a Regeneron Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top